“Biopreservation Market Report is set to have rapid growth due to consistent drug developments, advent of advanced therapies in the field of biomedical research and significant rise in patient base requiring high-end treatment for chronic diseases at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report Biopreservation Market Report : By Product (Equipment, Media, LIMS), By Application (Regenerative Medicine, Bio-banking, Drug Discovery), By Cell Provider, Regional And Segment Forecasts
The global biopreservation market is poised for rapid growth between 2019 and 2029. The drivers include increasing healthcare expenditure, growing demand for preserving new-born’s stem cells, increasing R&D spending on research, and increasing adoption of regenerative medicine.
An increase in healthcare costs is also expected to improve access to quality health care and advanced products, which include biopreservation facilities, thus expanding growth prospects. In addition, hospitals, gene banks and biobanks, which are significant end users for this market, are encouraging key players to develop technologically advanced biopreservation products to improve patient outcomes.
The presence of government health initiatives that provide funds, grants and research contracts have led to an accelerated growth of research and development activities carried out by various companies. This, in turn, has led to the expansion of the possibility of adopting advanced bioconservation services, which is foreseen for the rate of fuel penetration during the forecast period.
Technological advances in biopreservation processes are also important growth factors that contribute to the market. Advances include the change in the formulation of hypothermic conservation solutions, next-generation cryopreservation solutions and design and integration with nanoscale technologies. These technological updates have led to the conservation and long-term storage of complex organs and tissues of great importance in regenerative medicine and organ transplantation.
Leading companies featured in the report include BioLife Solutions Inc., BioCision, Biomatrica, Chart MVE Biomedical, TissueGene, LabVantage Solutions, Panasonic Biomedical, Qiagen, Taylor-Wharton Cryogenics and Thermo Fisher Scientific
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.